Suppr超能文献

接受新辅助放化疗和术后辅助放化疗的胸段食管鳞状细胞癌患者复发模式的比较。

Comparison of recurrence patterns between patients with thoracic esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and postoperative adjuvant chemoradiotherapy.

作者信息

Ni Kunhan, Huang Yixuan, Lu Simiao, Jiang Longlin, Zhang Huan, He Wenwu, Wang Chenghao, Zhou Qiang, Li Haojun, Li Jialong, Wang Kangning, Liu Guangyuan, Fang Qiang, Peng Lin, Leng Xuefeng, Han Yongtao

机构信息

Department of Thoracic Surgery, the Affiliated Hospital of Southwest Medical University, Sichuan, Luzhou, China.

Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China (UESTC), Chengdu, China.

出版信息

Front Oncol. 2025 Jun 16;15:1604808. doi: 10.3389/fonc.2025.1604808. eCollection 2025.

Abstract

PURPOSE

To compare the recurrence patterns and survival outcomes between patients with esophageal squamous cell carcinoma (ESCC) treated with neoadjuvant chemoradiotherapy (NCRT) and adjuvant chemoradiotherapy (ACRT).

METHODS

We retrospectively analyzed 267 patients with locally advanced ESCC who received treatment at Sichuan Cancer Hospital and Institute (Chengdu, China) between January 2018 and December 2020. Based on different treatment protocols, the patients were divided into two groups: NCRT (n=181) and ACRT (n=86). After propensity score matching, each group included 74 patients. This study compared the recurrence types, sites, frequencies, and timing, as well as overall survival (OS), disease-free survival (DFS), and prognostic risk factors between the two groups.

RESULTS

The recurrence rates in the NCRT and ACRT groups were 59.5% (44/74) and 33.8% (25/74), respectively; the difference was statistically significant (P=0.002). Recurrences primarily occurred within 2 years following esophagectomy. The ACRT group had a higher 3-year OS rate than the NCRT group (67.8% versus [vs.] 50.6%, respectively; P=0.019). In the subgroup of patients with local recurrence, the 3-year OS rate was higher in the NCRT group compared to the ACRT group (53.8% vs. 0%, respectively; P=0.029). In terms of DFS, the ACRT group exhibited better results than the NCRT group (P<0.001). Multivariate analysis revealed that pathological N staging was an independent risk factor affecting the OS prognosis of patients in the NCRT group. Margin status and pathological T staging were identified as independent risk factors influencing OS in the ACRT group, while sex and treatment regimen were independent risk factors affecting DFS in patients with postoperative pathological lymph node positivity.

CONCLUSION

There was significant difference in the OS and DFS prognosis of patients with ESCC treated with NCRT and ACRT. Recurrence primarily occurs within 2 years following esophagectomy. The recurrence rate was higher in the NCRT group compared to the ACRT group. Patients with early recurrence had a poorer survival prognosis compared to those with late recurrence. Pathological N staging was identified as an independent risk factor affecting OS in the NCRT group. Furthermore, margin status and pathological T staging were independent risk factors influencing OS in the ACRT group.

摘要

目的

比较接受新辅助放化疗(NCRT)和辅助放化疗(ACRT)的食管鳞状细胞癌(ESCC)患者的复发模式和生存结果。

方法

我们回顾性分析了2018年1月至2020年12月期间在四川省肿瘤医院及研究所(中国成都)接受治疗的267例局部晚期ESCC患者。根据不同的治疗方案,将患者分为两组:NCRT组(n = 181)和ACRT组(n = 86)。经过倾向评分匹配后,每组包括74例患者。本研究比较了两组患者的复发类型、部位、频率和时间,以及总生存期(OS)、无病生存期(DFS)和预后危险因素。

结果

NCRT组和ACRT组的复发率分别为59.5%(44/74)和33.8%(25/74);差异具有统计学意义(P = 0.002)。复发主要发生在食管切除术后2年内。ACRT组的3年OS率高于NCRT组(分别为67.8%对[vs.]50.6%;P = 0.019)。在局部复发的患者亚组中,NCRT组的3年OS率高于ACRT组(分别为53.8%对0%;P = 0.029)。在DFS方面,ACRT组的结果优于NCRT组(P < 0.001)。多因素分析显示,病理N分期是影响NCRT组患者OS预后的独立危险因素。切缘状态和病理T分期被确定为影响ACRT组OS的独立危险因素,而性别和治疗方案是影响术后病理淋巴结阳性患者DFS的独立危险因素。

结论

接受NCRT和ACRT治疗的ESCC患者的OS和DFS预后存在显著差异。复发主要发生在食管切除术后2年内。NCRT组的复发率高于ACRT组。早期复发患者的生存预后比晚期复发患者差。病理N分期被确定为影响NCRT组OS的独立危险因素。此外,切缘状态和病理T分期是影响ACRT组OS的独立危险因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f02b/12206882/9eb346a40746/fonc-15-1604808-g001.jpg

相似文献

4
Clinical efficacy of different neoadjuvant therapies for resectable esophageal squamous cell carcinoma.
World J Surg Oncol. 2025 Jun 20;23(1):243. doi: 10.1186/s12957-025-03897-w.
5
Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.
Cochrane Database Syst Rev. 2022 Aug 22;8(8):CD010260. doi: 10.1002/14651858.CD010260.pub3.
6
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
9
Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer.
Cochrane Database Syst Rev. 2017 Aug 22;8(8):CD010511. doi: 10.1002/14651858.CD010511.pub2.
10
Postoperative adjuvant chemotherapy in rectal cancer operated for cure.
Cochrane Database Syst Rev. 2012 Mar 14;2012(3):CD004078. doi: 10.1002/14651858.CD004078.pub2.

本文引用的文献

1
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
2
Neoadjuvant immunotherapy for resectable esophageal cancer: A review.
Front Immunol. 2022 Dec 8;13:1051841. doi: 10.3389/fimmu.2022.1051841. eCollection 2022.
3
Prognostic value of recurrence pattern in locally advanced esophageal squamous cell carcinoma: Results from the phase III trial NEOCRTEC5010.
J Thorac Cardiovasc Surg. 2023 Mar;165(3):888-897. doi: 10.1016/j.jtcvs.2022.08.009. Epub 2022 Aug 20.
4
Trimodality Approach for Esophageal Malignancies.
Surg Clin North Am. 2021 Jun;101(3):453-465. doi: 10.1016/j.suc.2021.03.007.
5
Esophageal Cancer: An Updated Review.
South Med J. 2021 Mar;114(3):161-168. doi: 10.14423/SMJ.0000000000001226.
6
Postoperative Adjuvant Therapy for Patients with pN+ Esophageal Squamous Cell Carcinoma.
Biomed Res Int. 2021 Jan 22;2021:8571438. doi: 10.1155/2021/8571438. eCollection 2021.
9
Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1).
Eur J Cancer. 2021 Feb;144:232-241. doi: 10.1016/j.ejca.2020.11.039. Epub 2020 Dec 26.
10
Multimodality approaches to control esophageal cancer: development of chemoradiotherapy, chemotherapy, and immunotherapy.
Esophagus. 2021 Jan;18(1):25-32. doi: 10.1007/s10388-020-00782-1. Epub 2020 Sep 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验